David Frazier serves as Global Vice Chair of Latham’s Intellectual Property Litigation Practice. He represents clients in complex biopharmaceutical patent litigation and provides strategic counseling across the life sciences industry, particularly biologics, antibodies, cell therapy, gene editing, and other emerging technologies.
A trailblazer in defending cutting-edge pharmaceutical products against infringing biosimilars, David combines his sophisticated understanding of molecular biology with keen market insight to represent leading biotechnology and pharmaceutical companies in:
David has robust experience leading and co-leading biopharmaceutical patent litigation, as well in Patent Trial and Appeal Board (PTAB) proceedings and strategy. In multijurisdictional parallel proceedings, he coordinates with local counsel all over the world to implement seamless litigation strategy.
Before joining Latham, he was a partner in the patent litigation practice at a global intellectual property law firm.
A recognized leader at the firm, David has served as a member of the firm’s Recruiting Committee. David maintains an active pro bono practice, including representing clients in veterans’ rights matters.
David's experience includes representing:
Firm honored for securing high-profile and precedent-setting IP litigation wins across practices, industries, and jurisdictions.
IP Litigation Practice recognized by Law360 for victories in several high-profile matters for LG Energy Solution, Peloton, and Astellas.
IP Litigation Practice recognized by Law360 for victories in several high-profile matters for LG Energy Solutions, Peloton, and Astellas.